(RTTNews) - Adaptive Biotechnologies Corp. (ADPT), Tuesday announced the launch of an enhanced version of its clonoSEQ assay for measurable residual disease or MRD detection in diffuse large B-cell ...
In this interview, we speak with the University of Warwick spin-out Cryologyx about their innovative new technology that hopes to revolutionize cell-based assays for researchers across life sciences ...
LOVELAND, Colo., Sept. 9, 2021 /PRNewswire/ -- Heska Corporation (NASDAQ: HSKA - News; "Heska" or the "Company"), a leading global provider of advanced veterinary diagnostic and specialty products, ...
Newcells offers a range of physiologically-relevant and functionally-validated iPSC and primary-cell models to support drug developers de-risk pre-clinical decision-making and improve clinical ...
PENZBERG, Germany--(BUSINESS WIRE)-- Roche (SIX: RO, ROG; OTCQX: RHHBY) and Exiqon (NASDAQ OMX: EXQ) join marketing forces for Roche Applied Science´s RealTime ready assays and Exiqon`s miRCURY LNA™ ...
Mesoblast has taken another step on the path toward its third attempt to win approval of its off-the-shelf therapy, exiting a meeting with the FDA convinced that new potency assay data and a ...
DELRAY BEACH, Fla.--(BUSINESS WIRE)--PanGIA Biotech–a pioneer in liquid biopsy technology–today announced its first international partnership, collaborating with Canary Oncoceutics (Canary Oncoceutics ...
BioIVT, a leading provider of research models and services for drug development, today announced that it has acquired Santa Clara, CA-based Optivia Biotechnology and its comprehensive portfolio of ...
SEATTLE, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NAUT) (NASDAQ: NAUT; or “Nautilus”), a company pioneering single-molecule proteome analysis, today announced the launch of an ...
PharmaCyte Biotech Announces Additional Quality Control Assay and Confirms Stability of CypCap Cells
LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes and malignant ascites using its signature ...
PanGIA Biotech, Inc. ("PanGIA") announced a peer-reviewed clinical study published in Diagnostics, "Urine-Based Machine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results